5 highlights from EyePoint Pharmaceuticals’ Q4

EyePoint Pharmaceuticals reported $8.6 million and $20.4 million in fourth-quarter and 2019 revenues, respectively.

Advertisement

Here are four other things to know from the quarter:

1. ASCs drove quarterly purchasing, culminating in a 111 percent increase over the third quarter of 2019, with repeat customers representing 98 percent of fourth-quarter order volume.

2. Despite strong revenue growth, EyePoint posted a $10.4 million loss on the quarter and a $56.8 million loss on the year.

3. During the quarter, EyePoint appointed George Elston CFO and issued a public offering of 15 million shares of common stock at a price of $1.45 per share.

4. EyePoint believes its combination of cash and cash equivalents, along with the proceeds from the public offering and incoming cash, will fund the company’s operations through 2021.

More articles on surgery centers:
Orthopedic spine & neurosurgery specialists join New York Rothman Orthopaedics ASC
North Carolina spine surgery center moves to renovated VA clinic
3 spine procedures that cost hundreds less at ASCs

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.